273 related articles for article (PubMed ID: 26577456)
1. Application of proteomics in non-small-cell lung cancer.
Cho WC
Expert Rev Proteomics; 2016; 13(1):1-4. PubMed ID: 26577456
[TBL] [Abstract][Full Text] [Related]
2. Proteomics biomarkers for non-small cell lung cancer.
Kisluk J; Ciborowski M; Niemira M; Kretowski A; Niklinski J
J Pharm Biomed Anal; 2014 Dec; 101():40-9. PubMed ID: 25175018
[TBL] [Abstract][Full Text] [Related]
3. Proteomic-Based Approaches for the Study of Cytokines in Lung Cancer.
Marrugal Á; Ojeda L; Paz-Ares L; Molina-Pinelo S; Ferrer I
Dis Markers; 2016; 2016():2138627. PubMed ID: 27445423
[TBL] [Abstract][Full Text] [Related]
4. Hypoxic markers in non-small cell lung cancer (NSCLC) - A review.
Xu FX; Zhang YL; Liu JJ; Zhang DD; Chen HB
Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):849-52. PubMed ID: 27010140
[TBL] [Abstract][Full Text] [Related]
5. Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins.
Jin Y; Wang J; Ye X; Su Y; Yu G; Yang Q; Liu W; Yu W; Cai J; Chen X; Liang Y; Chen Y; Wong BH; Fu X; Sun H
Br J Cancer; 2016 Mar; 114(5):532-44. PubMed ID: 26908325
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy.
Aoki MN; Amarante MK; de Oliveira CEC; Watanabe MAE
Anticancer Agents Med Chem; 2018; 18(15):2070-2077. PubMed ID: 30147015
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of reverse phase protein array (RPPA)-based pathway-activation profiling in 84 non-small cell lung cancer (NSCLC) cell lines as platform for cancer proteomics and biomarker discovery.
Ummanni R; Mannsperger HA; Sonntag J; Oswald M; Sharma AK; König R; Korf U
Biochim Biophys Acta; 2014 May; 1844(5):950-9. PubMed ID: 24361481
[TBL] [Abstract][Full Text] [Related]
8. Proteomic biomarkers for lung cancer progression.
Ren Y; Zhao S; Jiang D; Feng X; Zhang Y; Wei Z; Wang Z; Zhang W; Zhou QF; Li Y; Hou H; Xu Y; Zhou F
Biomark Med; 2018 Mar; 12(3):205-215. PubMed ID: 29424557
[TBL] [Abstract][Full Text] [Related]
9. [Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].
Ostoros G; Döme B; Strausz J; Tímár J
Magy Onkol; 2010 Jun; 54(2):137-43. PubMed ID: 20576590
[TBL] [Abstract][Full Text] [Related]
10. Shotgun and Targeted Plasma Proteomics to Predict Prognosis of Non-Small Cell Lung Cancer.
Li QR; Liu YS; Zeng R
Methods Mol Biol; 2017; 1619():385-394. PubMed ID: 28674898
[TBL] [Abstract][Full Text] [Related]
11. Proteome analysis of non-small cell lung cancer cell line secretomes and patient sputum reveals biofluid biomarker candidates for cisplatin response prediction.
Böttger F; Schaaij-Visser TB; de Reus I; Piersma SR; Pham TV; Nagel R; Brakenhoff RH; Thunnissen E; Smit EF; Jimenez CR
J Proteomics; 2019 Mar; 196():106-119. PubMed ID: 30710758
[TBL] [Abstract][Full Text] [Related]
12. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
Osmani L; Askin F; Gabrielson E; Li QK
Semin Cancer Biol; 2018 Oct; 52(Pt 1):103-109. PubMed ID: 29183778
[TBL] [Abstract][Full Text] [Related]
13. Prognostic markers in resectable non-small cell lung cancer.
Strauss GM
Hematol Oncol Clin North Am; 1997 Jun; 11(3):409-34. PubMed ID: 9209903
[TBL] [Abstract][Full Text] [Related]
14. Summary of presentations from the 46th Annual Meeting of the American Society of Clinical Oncology: focus on non-small cell lung cancer (2010).
Stinchcombe TE; Baggstrom MQ; Somaiah N; Simon GR; Govindan R
J Thorac Oncol; 2011 Jan; 6(1):227-32. PubMed ID: 21178721
[TBL] [Abstract][Full Text] [Related]
15. Proteome screening of pleural effusions identifies IL1A as a diagnostic biomarker for non-small cell lung cancer.
Li Y; Lian H; Jia Q; Wan Y
Biochem Biophys Res Commun; 2015 Feb; 457(2):177-82. PubMed ID: 25554695
[TBL] [Abstract][Full Text] [Related]
16. From Uniplex to Multiplex Molecular Profiling in Advanced Non-Small Cell Lung Carcinoma.
Ileana EE; Wistuba II; Izzo JG
Cancer J; 2015; 21(5):413-24. PubMed ID: 26389767
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of Twist, Slug, and Foxc2 expression in stage I non-small-cell lung cancer after curative resection.
Jiang W; Pang XG; Wang Q; Shen YX; Chen XK; Xi JJ
Clin Lung Cancer; 2012 Jul; 13(4):280-7. PubMed ID: 22178381
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor biomarkers in non-small-cell lung cancer: a riddle, wrapped in a mystery, inside an enigma.
Shepherd FA; Tsao MS
J Clin Oncol; 2010 Feb; 28(6):903-5. PubMed ID: 20100955
[No Abstract] [Full Text] [Related]
19. Predicting Diagnostic Gene Biomarkers for Non-Small-Cell Lung Cancer.
Liang B; Shao Y; Long F; Jiang SJ
Biomed Res Int; 2016; 2016():3952494. PubMed ID: 27579312
[TBL] [Abstract][Full Text] [Related]
20. Clinical implication of microrna for lung cancer.
Wang Y; Zhang X; Liu L; Li H; Yu J; Wang C; Ren X
Cancer Biother Radiopharm; 2013 May; 28(4):261-7. PubMed ID: 23496233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
